TACTI-mel – A multicentre, open label, dose escalation Phase I study in patients with unresectable or metastatic melanoma receiving Study drug as an adjunctive therapy to anti-PD-1 therapy with pembrolizumab.
TACTI-mel – A multicentre, open label, dose escalation Phase I study in patients with unresectable or metastatic melanoma receiving Study drug as an adjunctive therapy to anti-PD-1 therapy with pembrolizumab.